NEXI Stock Overview
A clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NexImmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$28.69 |
| 52 Week Low | US$0.20 |
| Beta | 1.69 |
| 11 Month Change | 60.85% |
| 3 Month Change | -54.55% |
| 1 Year Change | -80.45% |
| 33 Year Change | -99.82% |
| 5 Year Change | n/a |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely
Sep 07
Neximmune GAAP EPS of -$0.69 misses by $0.01
Aug 15NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers
Jul 14NexImmune: Selling For Under Cash Value
May 31Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation
May 26We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate
Dec 19Shareholder Returns
| NEXI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 38.3% | 2.5% | 2.2% |
| 1Y | -80.4% | 16.1% | 31.6% |
Return vs Industry: NEXI underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: NEXI underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| NEXI volatility | |
|---|---|
| NEXI Average Weekly Movement | 43.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NEXI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NEXI's weekly volatility (43%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 6 | Craig Jalbert | www.neximmune.com |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials.
NexImmune, Inc. Fundamentals Summary
| NEXI fundamental statistics | |
|---|---|
| Market cap | US$488.13k |
| Earnings (TTM) | -US$20.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NEXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEXI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.62m |
| Earnings | -US$20.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NEXI perform over the long term?
See historical performance and comparison